These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 23494865)

  • 1. Pyloric stenosis associated Crohn's disease responding to adalimumab therapy.
    Gaggar S; Scott J; Thompson N
    World J Gastrointest Pharmacol Ther; 2012 Dec; 3(6):97-9. PubMed ID: 23494865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyloric stenosis as a manifestation of isolated gastric Crohn's disease responding to intralesional steroid injection and balloon dilation: a case report.
    Balendran K; Udumalagala S; Nawaraththne NMM
    J Med Case Rep; 2019 Nov; 13(1):331. PubMed ID: 31718712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyloric Stenosis: A Rare Manifestation of Crohn's Disease.
    Ramachandran R; Then E; Grantham T; Parvataneni S; Gaduputi V
    J Community Hosp Intern Med Perspect; 2022; 12(1):39-42. PubMed ID: 35711859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pyloric stenosis as a presenting clinical pattern of Crohn's disease].
    Chávez-Velarde OE; Hernández-Ramírez DA; Martínez-Gen R; Gómez-Jiménez LM
    Rev Med Inst Mex Seguro Soc; 2010; 48(5):553-6. PubMed ID: 21205507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.
    Dretzke J; Edlin R; Round J; Connock M; Hulme C; Czeczot J; Fry-Smith A; McCabe C; Meads C
    Health Technol Assess; 2011 Feb; 15(6):1-244. PubMed ID: 21291629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Actual Anti-TNF Trough Levels Relate to Serum IL-10 in Drug-Responding Patients With Crohn's Disease.
    Zapater P; Almenara S; Gutiérrez A; Sempere L; García M; Laveda R; Martínez A; Scharl M; Cameo JI; Linares R; González-Navajas JM; Wiest R; Rogler G; Francés R
    Inflamm Bowel Dis; 2019 Jul; 25(8):1357-1366. PubMed ID: 30776076
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyloric stenosis due to Crohn's disease.
    Nakamura H; Yanai H; Miura O; Minamisono Y; Mitani N; Higaki S; Tada M; Okita K
    J Gastroenterol; 1998 Oct; 33(5):739-42. PubMed ID: 9773942
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early treatment with anti-tumor necrosis factor agents improves long-term effectiveness in symptomatic stricturing Crohn's disease.
    Rodríguez-Lago I; Hoyo JD; Pérez-Girbés A; Garrido-Marín A; Casanova MJ; Chaparro M; Fernández-Clotet A; Castro-Poceiro J; García MJ; Sánchez S; Ferreiro-Iglesias R; Bastón I; Piqueras M; Careda LEIB; Mena R; Suárez C; Cordón JP; López-García A; Márquez L; Arroyo M; Alfambra E; Sierra M; Cano N; Delgado-Guillena P; Morales-Alvarado V; Aparicio JC; Guerra I; Aulló C; Merino O; Arranz L; Hidalgo MA; Llaó J; Plaza R; Molina G; Torres P; Pérez-Galindo P; Romero MG; Herrera-deGuise C; Armesto E; Mesonero F; Frago-Larramona S; Benítez JM; Calvo M; Martín MDCL; Elorza A; Larena A; Peña E; Rodríguez-Grau MDC; Miguel-Criado J; Botella B; Olmos JA; López L; Aguirre U; Gisbert JP;
    United European Gastroenterol J; 2020 Nov; 8(9):1056-1066. PubMed ID: 32723069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.
    Hanauer SB; Sandborn WJ; Rutgeerts P; Fedorak RN; Lukas M; MacIntosh D; Panaccione R; Wolf D; Pollack P
    Gastroenterology; 2006 Feb; 130(2):323-33; quiz 591. PubMed ID: 16472588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
    Fidder HH; Singendonk MM; van der Have M; Oldenburg B; van Oijen MG
    World J Gastroenterol; 2013 Jul; 19(27):4344-50. PubMed ID: 23885145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe Crohn's DiseaSe (ACCESS) trial.
    Panaccione R; Loftus EV; Binion D; McHugh K; Alam S; Chen N; Guerette B; Mulani P; Chao J
    Can J Gastroenterol; 2011 Aug; 25(8):419-25. PubMed ID: 21912766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series.
    Cordero Ruiz P; Castro Márquez C; Méndez Rufián V; Castro Laria L; Caunedo Álvarez A; Romero Vázquez J; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 2011 Jun; 103(6):294-8. PubMed ID: 21736395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab - an effective and promising treatment for patients with fistulizing Crohn's disease: a case series.
    Kouklakis G; Efremidou EI; Zezos P; Liratzopoulos N; Souftas VD; Gatopoulou A; Simopoulos K; Manolas KJ
    J Med Case Rep; 2011 Mar; 5():109. PubMed ID: 21418588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.
    Colombel JF; Sandborn WJ; Rutgeerts P; Kamm MA; Yu AP; Wu EQ; Pollack PF; Lomax KG; Chao J; Mulani PM
    Am J Gastroenterol; 2009 May; 104(5):1170-9. PubMed ID: 19352339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers.
    Stoppino LP; Della Valle N; Rizzi S; Cleopazzo E; Centola A; Iamele D; Bristogiannis C; Stoppino G; Vinci R; Macarini L
    BMC Med Imaging; 2016 May; 16(1):37. PubMed ID: 27149857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Difficult-to-treat-pediatric Crohn's disease: focus on adalimumab.
    Zeisler B; Hyams JS
    Pediatric Health Med Ther; 2015; 6():33-40. PubMed ID: 29388607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.